| Necroptosis‐Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy W Um, H Ko, DG You, S Lim, G Kwak, MK Shim, S Yang, J Lee, Y Song, ... Advanced Materials 32 (16), 1907953, 2020 | 139 | 2020 |
| Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy J Choi, MK Shim, S Yang, HS Hwang, H Cho, J Kim, WS Yun, Y Moon, ... ACS nano 15 (7), 12086-12098, 2021 | 124 | 2021 |
| Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity S Yang, MK Shim, WJ Kim, J Choi, GH Nam, J Kim, J Kim, Y Moon, ... Biomaterials 272, 120791, 2021 | 113 | 2021 |
| Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery MK Shim, S Yang, IC Sun, K Kim Advanced Drug Delivery Reviews 183, 114177, 2022 | 103 | 2022 |
| Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy MK Shim, Y Moon, S Yang, J Kim, H Cho, S Lim, HY Yoon, JK Seong, ... Biomaterials 261, 120347, 2020 | 86 | 2020 |
| In situ one-step fluorescence labeling strategy of exosomes via bioorthogonal click chemistry for real-time exosome tracking in vitro and in vivo S Song, MK Shim, S Lim, Y Moon, S Yang, J Kim, Y Hong, HY Yoon, ... Bioconjugate chemistry 31 (5), 1562-1574, 2020 | 86 | 2020 |
| Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death Y Moon, MK Shim, J Choi, S Yang, J Kim, WS Yun, H Cho, JY Park, Y Kim, ... Theranostics 12 (5), 1999, 2022 | 79 | 2022 |
| Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance J Kim, MK Shim, S Yang, Y Moon, S Song, J Choi, J Kim, K Kim Journal of Controlled Release 330, 920-932, 2021 | 51 | 2021 |
| Doxorubicin-loaded PLGA nanoparticles for cancer therapy: molecular weight effect of PLGA in doxorubicin release for controlling immunogenic cell death Y Choi, HY Yoon, J Kim, S Yang, J Lee, JW Choi, Y Moon, J Kim, S Lim, ... Pharmaceutics 12 (12), 1165, 2020 | 51 | 2020 |
| All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy S Song, MK Shim, S Yang, J Lee, WS Yun, H Cho, Y Moon, JY Min, ... Bioactive Materials 28, 358-375, 2023 | 41 | 2023 |
| Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity S Yang, MK Shim, S Song, H Cho, J Choi, SI Jeon, WJ Kim, W Um, ... Biomaterials 290, 121841, 2022 | 36 | 2022 |
| Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy S Yang, IC Sun, HS Hwang, MK Shim, HY Yoon, K Kim Journal of Materials Chemistry B 9 (19), 3983-4001, 2021 | 33 | 2021 |
| Sustained and long-term release of doxorubicin from PLGA nanoparticles for eliciting anti-tumor immune responses J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon, J Kim, N Shim, H Cho, ... Pharmaceutics 14 (3), 474, 2022 | 28 | 2022 |
| Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy N Shim, SI Jeon, S Yang, JY Park, M Jo, J Kim, J Choi, WS Yun, J Kim, ... Biomaterials 289, 121806, 2022 | 21 | 2022 |
| Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light J Choi, IS Lee, JS Lee, S Jeon, WS Yun, S Yang, Y Moon, J Kim, J Kim, ... Biomaterials Research 26 (1), 56, 2022 | 20 | 2022 |
| Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography S Lim, HY Yoon, SJ Park, S Song, MK Shim, S Yang, SW Kang, DK Lim, ... Biomaterials 266, 120472, 2021 | 20 | 2021 |
| Cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy H Cho, MK Shim, S Yang, S Song, Y Moon, J Kim, Y Byun, CH Ahn, K Kim Pharmaceutics 14 (1), 83, 2021 | 17 | 2021 |
| Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity MK Shim, S Yang, J Park, JS Yoon, J Kim, Y Moon, N Shim, M Jo, Y Choi, ... Journal of Nanobiotechnology 20 (1), 436, 2022 | 14 | 2022 |
| Cathepsin B-responsive prodrugs for cancer-targeted therapy: Recent advances and progress for clinical translation SI Jeon, S Yang, MK Shim, K Kim Nano Research 15 (8), 7247-7266, 2022 | 12 | 2022 |
| Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug HY Kim, SH Um, Y Sung, MK Shim, S Yang, J Park, ES Kim, K Kim, ... Journal of Controlled Release 328, 222-236, 2020 | 10 | 2020 |